Mortality in patients with esophageal and gastroesophageal tumors treated with self-expandable stents
Mortalidad en pacientes con tumores de esófago y en región gastroesofágica manejados con prótesis autoexpandibles
DOI:
https://doi.org/10.15446/revfacmed.v64n3.52883Palabras clave:
Esophageal Neoplasms, Esophagogastric Junction, Esophageal Stenosis, Stents, Mortality (en)Cáncer esofágico, Unión esofagogástrica, Estenosis esofágica, Stents, Mortalidad (es)
Descargas
Introduction: Esophageal cancer is an aggressive disease and is the eighth cause of malignant tumors worldwide. To treat dysphagia, auto expandable prosthesis (AEP) are used in order to optimize the nutritional status and quality of life of the patients.
Objectives: To quantify patients’ mortality and to evaluate variables related with this outcome.
Materials and methods: Retrospective cohort study that involved 135 patients with esophageal malignant obstruction that required AEP insertion. Survival and incidence density rates were estimated. The effect of these variables on the probability of death was assessed by using Cox models.
Results: Overall mortality rate was 13.7 deaths per 100 patients/month (95%CI: 10.9-17.1). Univariate analysis showed significant differences in survival functions according to pre-intervention albumin levels and the prosthesis size (>12cm). In the Cox model, albumin level (HR=0.53, 95%CI 0.31 to 0.89) was the only significant result.
Conclusions: AEP represent a therapeutic option to improve symptoms in patients with advanced esophageal and gastroesophageal junction tumors. This technique has few complications and its clinical success is around 90%. Patients’ nutritional status and length of the stenosis caused by the tumor are variables that must be evaluated before performing a procedure as they seem to be related to mortality.
Introduction: Esophageal cancer is an aggressive disease and is the eighth cause of malignant tumors worldwide. To treat dysphagia, auto expandable prosthesis (AEP) are used in order to optimize the nutritional status and quality of life of the patients.
Objectives: To quantify patients’ mortality and to evaluate variables related with this outcome.
Materials and methods: Retrospective cohort study that involved 135 patients with esophageal malignant obstruction that required AEP insertion. Survival and incidence density rates were estimated. The effect of these variables on the probability of death was assessed by using Cox models.
Results: Overall mortality rate was 13.7 deaths per 100 patients/month (95%CI: 10.9-17.1). Univariate analysis showed significant differences in survival functions according to pre-intervention albumin levels and the prosthesis size (>12cm). In the Cox model, albumin level (HR=0.53, 95%CI 0.31 to 0.89) was the only significant result.
Conclusions: AEP represent a therapeutic option to improve symptoms in patients with advanced esophageal and gastroesophageal junction tumors. This technique has few complications and its clinical success is around 90%. Patients’ nutritional status and length of the stenosis caused by the tumor are variables that must be evaluated before performing a procedure as they seem to be related to mortality.
Introducción. El cáncer de esófago es una entidad agresiva y la octava causa de tumores malignos en el mundo. Para manejar la disfagia se insertan prótesis esofágicas autoexpandibles (PEA) que optimizan la ingesta y permiten mejorar el estado nutricional y la calidad de vida de los pacientes.
Objetivos. Cuantificar la mortalidad en los pacientes y evaluar las variables asociadas con este desenlace.
Materiales y métodos. Estudio de cohorte retrospectivo realizado en 135 pacientes con obstrucción esofágica maligna que requirieron inserción de PEA. Se estimó la función de supervivencia, se calcularon tasas de incidencia y se evaluó el efecto de las variables descritas sobre la probabilidad de morir utilizando modelos de Cox.
Resultados. La tasa de mortalidad fue de 13.7 muertes por 100 pacientes/mes (IC95%: 10.9-17.1). Los análisis univariados mostraron diferencias significativas en las funciones de supervivencia según niveles de albúmina previa y tamaño de la prótesis (>12cm). En el modelo de Cox solo resultó significativo el nivel de albúmina (HR=0.53, IC95%: 0.31-0.89).
Conclusiones. Las PEA representan una alternativa de mejoría de síntomas en pacientes con tumores esofágicos en estadios avanzados. Esta técnica presenta pocas complicaciones y tiene probabilidades de éxito técnico y clínico cercanas al 90%. El estado nutricional del paciente y la longitud de la estenosis producida por el tumor son variables que deben evaluarse antes de cada procedimiento ya que parecen relacionarse con la mortalidad.
Referencias
Okines A, Sharma B, Cunninghan D. Perioperative management of esophageal cancer. Nat. Rev. Clin. Oncol. 2010;7(4):231-8.
http://doi. org/fk42w9.
Bader F, Anwar N, Mahmood S. Geographical variation in the epidemiology of esophageal cancer in Pakistan. Asian Pac. J. Cancer Prev. 2005;6(2):139-42.
International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, and Mortality Worldwide in 2012. Lyon: World Health Organization; 2013 [cited 2015 Feb 16]. Available from: https://goo. gl/yTGbwJ.
Eslick GD. Epidemiology of esophageal cancer. Gastroenterol. Clin. Noth Am. 2009;38(1):17-25. http://doi. org/d3ksk8.
Freeman RK, Ascioti AJ, Mahidhara RJ. Palliative Therapy for Patients with Unresectable Esophageal Carcinoma. Surg. Clin. Noth Am. 2012;92(5):1337-51. http://doi. org/bkrn.
Siddiqui AA, Sarkar A, Beltz S, Lewis J, Loren D, Kowalski T, et al. Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy. Gastrointest. Endosc. 2012;76(1):44-51. http://doi. org/f2h2rx.
Lambert R. Treatment of esophagogastric tumors. Endoscopy. 2000;32(4):322-30. http://doi. org/bz59gw.
Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, et al. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009;115(3):508-16. http://doi. org/dw8h7r.
Stewart DJ, Balamurugan R, Everitt NJ, Ravi K. Ten-year experience of esophageal self-expanding metal insertion at a single institution. Dis. Esophagus. 2013;26(3):276-81. http://doi. org/bkrp.
Xinopoulos D, Dimitroulopoulos D, Moschandrea I, Skordilis P, Bazinis A, Kontis M, et al. Natural course of inoperable esophageal cancer treated with metallic expandable stents: Quality of life and cost-effectiveness analysis. J. Gastroenterol. Hepatol. 2004:19(12):1397-402. http://doi. org/d8w7tp.
Gray RT, O’Donnell ME, Scott RD, McGuigan JA, Mainie I. Self-expanding metal stent insertion for inoperable esophageal carcinoma in Belfast: an audit of outcomes and literature review. Dis. Esophagus. 2011;24(8):569-74. http://doi. org/c2fwjv.
Eroglu A, Turkyilmaz A, Subasi M, Karaoglanglu N. The use of self-expandable metallic stents for palliative treatment of inoperable esophageal cancer. Dis. Esophagus. 2010;23(1):64-70. http://doi. org/cvzf2m.
Dobrucali A, Caglar E. Palliation of malignant esophageal obstruction and fistulas with self expandable metallic stents. World J. Gastroenterol. 2010;16(45):5739-45. http://doi. org/c34wmh.
Castaño R, Álvarez O, Lopera J, Ruiz MH, Juliao F, Sanín E, et al. Endoprótesis metálicas autoexpandibles en la obstrucción maligna esofágica y gastroduodenal. Rev. Colomb. Cir. 2005;20(1):33-48.
Johnson E, Enden T, Noreng HJ, Holck-Steen A, Gjerlaug BE, Morken T, et al. Survival and complications after insertion of self-expandable metal stents for malignant oesophageal stenosis. Scand. J. Gastroenterol. 2006;41(3):252-6. http://doi. org/fh6rzx.
Wilkes EA, Jackson LM, Cole AT, Freeman JG, Gddard AF. Insertion of expandable metallic stents in esophageal cancer without fluoroscopy is safe and effective: a 5-year experience. Gastrointest. Endosc. 2007;65(6):923-9. http://doi. org/b5thjn.
Lambert R. Insertion of expandable metallic stents in esophageal cancer without fluoroscopy: is it safe? Gastrointest. Endosc. 2007;65(6);929-31. http://doi. org/drdmj5.
Song HY, Do YS, Han YM, Sung KB, Choi EK, Sohn KH, et al. Covered, expandable esophageal metallic stent tubes: experiencies in 119 patients. Radiology. 1994;193(3):689-95. http://doi. org/bkrq.
Sabharwal T, Morales JP, salter R, Adam A. Esophageal cancer: self-expanding metallic stents. Abdom. Imaging. 2005;30(4):456-64. http://doi. org/fktvw6.
Na HK, Song HY, Kim JH, Park JH, Kang MK, Lee J, et al. How to design the optimal self-expandable oesophageal metallic stents: 22 years of experience in 645 patients with malignant strictures. Eur. Radiol. 2013;23(3):786-96. http://doi. org/bkrr.
Nwogu C. RE: Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses, by Griffiths E, Brummell Z, Gorthi G, et al. J. Surg. Oncol. 2006;93(4):257. http://doi. org/bksmdg.
Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Wech IM. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J. Surg. Oncol. 2006;93(4):258-67.
http://doi. org/dvbbfx.
Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the US: the importance of tumor length and lymph node status. Cancer. 2002;95(7):1434-43. http://doi. org/fwbmnz.
Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang Hw, Fang FM, et al. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother. Oncol. 2009;92(2):270-5. http://doi. org/drnjmr.
Dimensions
PlumX
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2017 Revista de la Facultad de Medicina

Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-








